Suicide gene therapy and the control of graft-vs-host disease-Reference-Cited by-同舟云学术

Suicide gene therapy and the control of graft-vs-host disease

Published:2004-09 Issue:3 Volume:17 Page:453-463
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Introna Martino,Rambaldi Alessandro

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference58 articles.

1. Prodrug-activating systems in suicide gene therapy;Springer;Journal of Clinical Investment,2000

2. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy;Moolten;Cancer Research,1986

3. Targeting of an inducible toxic phenotype in animal cells;Borrelli;Proceedings of the National Academy of Sciences, USA,1988

4. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency;Heyman;Proceedings of the National Academy of Sciences USA,1989

5. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine;Fyfe;Journal of Biological Chemistry,1978

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-directed Double Suicide Gene Therapy Targeting of MUC1- Positive Leukemia Cells In Vitro and In Vivo;Current Gene Therapy;2013-12-31

2. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease;Immunotherapy;2012-04

3. OuaSelect, a novel ouabain-resistant human marker gene that allows efficient cell selection within 48 h;Gene Therapy;2007-09-27